Aligos Therapeutics, Inc. (ALGS) SEC Filings — 2025
12 SEC filings for Aligos Therapeutics, Inc. (ALGS) in 2025.
Filings
- Aligos' Q3 Loss Widens to $31.5M Amid Rising R&D, Warrants Boost YTD — 10-Q · Nov 6, 2025
- Aligos Therapeutics, Inc. 8-K Filing — 8-K · Nov 6, 2025
- Aligos Therapeutics Files 8-K on Financials — 8-K · Aug 6, 2025
- Aligos Reports Q2 Net Loss of $18.5M, Advances Pipeline — 10-Q · Aug 6, 2025
- Aligos Therapeutics Files 8-K with Corporate Governance Updates — 8-K · Jun 26, 2025
- Aligos Therapeutics Files 8-K on Financials — 8-K · May 6, 2025
- Aligos Therapeutics Q1 2025 10-Q: Funding, Licensing, R&D — 10-Q · May 6, 2025
- Aligos Therapeutics Files 2025 Proxy Statement — DEF 14A · Apr 28, 2025
- Aligos Therapeutics Files 8-K on Financials — 8-K · Mar 10, 2025
- Aligos Therapeutics Files 2024 10-K, Details Key Agreements — 10-K · Mar 10, 2025
- Aligos Therapeutics Files 8-K with Key Agreements and Disclosures — 8-K · Feb 12, 2025
- Aligos Therapeutics Announces Executive and Director Changes — 8-K · Feb 3, 2025